Latest From Biotest AG
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Biotest AG
- Senior Management
Michael Ramroth, CFO
Joachim Herborg, EVP, Commercial Operations
Joerg Schuettrumpf, MD, SVP, Global Research
Georg Floss, COO
- Contact Info
Phone: (49) 61 03 8 01 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.